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Sir,
The issue of anthracycline dose and liver dysfunction is an impor-
tant one, and we were very interested in the work of Dobbs et al
(1998) about oncologist’s sensibility for dose modification in
patients with liver dysfunction and breast cancer. Usually, current
recommendations suggest to use liver function tests, and particu-
larly serum bilirubin, for dose modification. According to our
group this issue needs some considerations:
1. Serum bilirubin levels do not reflect a histological damage of
liver. If a patient has Gilbert’s syndrome, bilirubinaemia levels
can increase without significant liver disease (Fevery and
Blanckaert, 1991).
2. Conventional so-called liver function tests (AlT, AsT, alkaline
phosphatase, GGT, etc.) can reflect liver damage, but they do
not correlate with an impairment of liver function. Recent
studies observed that quantitative liver function tests can be
used for modification of the doses especially because they
reflect an underlying liver lesion (Cannizzaro et al, 1996).
3. Treatment with biliary acids (ursodesossicolic acid or others)
can be employed to normalize alterated levels of cholestatic
indices, such as alkaline phosphatases or GGT, and biliru-
binaemia in patients with chronic liver disease and can reduce
liver damage (Saksena and Tandon, 1997).
All patients with liver dysfunction are usually excluded from
clinical trials using chemotherapy regimens as they have eligibility
criteria that require ‘normal’ liver function, or at best bilirubin
values < 1.5 mg dl/l and ALT < 60 IU ml/l. In clinical practice, in
the presence of abnormal liver biochemistry, oncologists may be
tempted to avoid validated chemotherapy regimens and choose
other forms of treatment or to reduce dosage.
‘Adjuvant’ treatments after surgery are the only ones capable of
prolonging disease-free survival and even overall survival, and we
know that dose reductions may compromise overall treatment
results (Hryniuk et al, 1987). Furthermore, in an attempt to define
guidelines for dose modifications it is important in our mind to
distinguish different clinical conditions in breast cancer treatment:
1. Liver function tests might be abnormal because of liver
invasion by cancer cells (cholestatic indices).
2. The liver dysfunction might be due to underlying chronic liver
disease and the patient has a high risk cancer which needs
intensive chemotherapy.
3. The liver dysfunction might be due to hepatotoxic changes
from chemotherapeutic drugs.
Anthracycline is one the best cytostatic drugs for breast cancer.
Instead of reducing the dose intensity, alternative strategies
(weekly treatment, for instance) should be considered which
permit to reduce tumour burden with small repeated doses of drug.
As anthracycline-containing regimens are otherwise increasingly
used in adjuvant settings, better dose modification guidelines are
urgently needed. On the other hand, we should not forget that
breast cancer patients may have a relatively long life-expectancy
which could reveal late effects of cytotoxic drugs on liver.
We think there is the urgent need to develop newer systems,
including quantitative liver function tests (MEGX test, amino-
pyrine breath test, etc.) in order to evaluate and monitor liver
function during oncological treatments since not only anthracy-
cline, but many anticancer drugs, are excreted by the liver or need
it for their activation.
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